Ovarian cancer patients are considered platinum refractory if their disease worsens during
primary platinum treatment or if they have no effect of the treatment. This constitutes a
major therapeutic problem and new treatment approaches are highly needed.
Cabazitaxel (Jevtana®) is a new taxane with effect in breast and prostatic cancer. In both
tumors it has effect in patients refractory to taxotere. Consequently, it could be
anticipated that cabazitaxel may have an effect in platinum refractory ovarian cancer.